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ABSTRACT:
The Notch signaling pathway drives proliferation, differentiation, apoptosis, cell fate, and 
maintenance of stem cells in several tissues. Aberrant activation of Notch signaling has 
been described in several tumours and in gastric cancer (GC), activated Notch1 has been 
associated with de-differentiation of lineage-committed stomach cells into stem progenitors 
and GC progression. However, the specific role of the Notch1 ligand (DLL1) in GC has not 
yet been elucidated. To assess the role of DLL1 in GC cancer, the expression of Notch1 and 
its ligands DLL1 and Jagged1, was analyzed in 8 gastric cancer cell lines (KATOIII, SNU601, 
SNU719, AGS, SNU16, MKN1, MKN45, TMK1). DLL1 expression was absent in KATOIII, SNU601, 
SNU719 and AGS. The lack of DLL1 expression in these cells was associated with promoter 
hypermethylation and 5-aza-2’deoxycitidine caused up-regulation of DLL1. The increase in DLL1 
expression was associated with activation of Notch1 signalling, with an increase in cleaved 
Notch1 intracellular domain (NICD) and Hes1, and down-regulation in Hath1. Concordantly, 
Notch1 signalling was activated with the overexpression of DLL1. Moreover, Notch1 signalling 
together with DLL1 methylation were evaluated in samples from 52 GC patients and 21 healthy 
control as well as in INS-GAS mice infected with H. pylori and randomly treated with eradication 
therapy.  In GC patients, we found a correlation between DLL1 and Hes1 expression, while 
DLL1 methylation and Hath1 expression were associated with the diffuse and mixed type of 
gastric cancer. Finally, none of the samples from INS-GAS mice infected with H. pylori, a model 
of intestinal-type gastric tumorigenesis, showed promoter methylation of DLL1. This study 
shows that Notch1 activity in gastric cancer is controlled by the epigenetic silencing of the 
ligand DLL1, and that Notch1 inhibition is associated with the diffuse type of gastric cancer.
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INTRODUCTION
Although there is an overall worldwide decline in 
incidence, gastric cancer (GC) is still the fourth more 
common cancer and the second leading cause of cancer-
related deaths [1]. It is known that the risk factors for this 
disease include diet, Helicobacter (H.) pylori infection 
and genetic alterations [2-3]. To date, the mechanisms 
controlling GC aggressiveness are not fully elucidated.
Notch signaling is a key pathway in self-renewal 
of stem cells, cell fate determination and terminal 
differentiation of proliferating cells [4]. The mammalian 
genome encodes for four Notch receptors (Notch 1-4) 
and five Notch ligands (Delta-Like1, Delta-Like3, Delta-
Like4, Jagged1 and Jagged2). After ligand binding, the 
Notch extracellular domain is cleaved by the ADAM 
proteases and then subjected to further cleavage by 
the γ-secretase complex with the release of the Notch 
intracellular domaine (NICD). After translocating into 
the nucleus, NICD acts as a transcription factor for its 
downstream targets [5-8]. The best-characterized Notch 
effectors are the bHLH protein Hairy/Enhancer of Split 
(HES), which suppress the expression of downstream 
genes such as Neurogenin3 and Hath1. Importantly, these 
genes play a critical role in cell lineage commitment and 
drive cell fates and differentiation in several tissues [8-
9]. In particular, in the gastrointestinal (GI) tract, Notch 
signaling drives the fate of immature progenitors toward 
absorptive or secretory lineage. In the intestine, Notch1 
controls the differentiation towards enterocytes, and its 
inhibition converts colonic proliferative crypt cells into 
post-mitotic goblet cells [8]. Moreover, Hes1-/- mutant 
mice develop intestinal abnormalities with a relative 
increase in mucus secreting and enteroendocrine cells at 
the expense of absorptive enterocytes, whereas Math1-
deficient mice display a ‘reciprocal phenotype’ [10-11]. 
In the stomach, Notch activity is involved in the inhibition 
of chief cell differentiation and Hath1 over-expression 
enhances MUC5AC expression in the mucous neck cells 
of the fundic glands [10, 12]. Notch signaling occurs in 
the mouse stomach during development and is restricted 
to the isthmus in adult glands. Recently, Notch activation 
in lineage committed stomach epithelial cells has been 
shown to induce de-differentiation into stem cells, 
enhances proliferation and adenomas whereas Notch 
activation in the antral portion of the stomach does not 
affect proliferation [13]. 
Among the entire panel of the Notch ligands, Delta-
Like1 (DLL1) has been demonstrated to be frequently 
involved in the assignment of the cell lineage fate. In 
zebrafish intestines, the inhibition of Delta-Notch signaling 
enhances the secretory differentiation [14]. Interestingly, 
inactivation of DLL1 in mice intestinal tissue mimics 
the inactivation of Notch1 as it results in an increase 
number of goblet cells, indicating that DLL1 is critical in 
the control of Notch1 in this system [15]. However, the 
interaction between DLL1 and Notch1 is responsible for 
regulating glandular differentiation in chicken stomach 
development [16]. Finally, mice deficient in DLL1 have 
an accelerated differentiation of pancreatic endocrine 
cells at the expenses of the exocrine component  [17].
In this study we assessed the role of DLL1-Notch1 
signaling in gastric carcinogenesis, given that an imbalance 
of self-renewal homeostasis is an essential requirement 
for tumorigenesis and deregulated expression of Notch 
signaling components frequently occurs in tumors [7, 
18]. For this purpose, we evaluated the Notch1 cascade in 
gastric cancer cell lines and we found a specific correlation 
between DLL1 expression and promoter hypermethylation. 
The relationship between DLL1 expression and Notch1 
activation was demonstrated in vitro by pharmacological 
studies and by utilizing transgenic models. Moreover, our 
in vivo data showed that the epigenetic silencing of DLL1 
with repression of the Notch1 cascade was associated with 
diffuse gastric carcinogenesis. These results were further 
confirmed by the INS-GAS murine model of gastric 
intestinal carcinogenesis, in which DLL1 was expressed 
and promoter methylation was absent.
MATERIALS AND METHODS
Cell lines and treatments
Gastric cancer (GC) cell lines AGS, KATOIII, 
SNU16, SNU601, TMK1 and MKN45 were a kind gift 
from Dr. Antonia R. Sepulveda; MKN1 was kindly 
provided by Dr. Richard Hamelin; SNU719 was kindly 
given by Dr. Dong K. Chang. STR profiling was performed 
for cell lines authentication.
Cells were cultured in RPMI-1640 Medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% of 
fetal bovine serum (Invitrogen), 100 U/ml penicillin, 100 
μg/ml streptomycin and 2mM glutamine (Invitrogen). 
Cells were maintained at 37°C in a 5% CO2 incubator. 
5-aza-2’deoxycitidine was purchased by Sigma-
Aldrich (St.Louis, MO) and the treatment was performed 
on AGS and SNU719 cell lines at 10 µM for 5 days. 
The full DLL1 coding sequence was cloned into 
the pCMV-Tag1 expression vector (Stratagene, La Jolla, 
CA), using BamHI and HindIII restriction enzymes 
(NEB, Ipswich, MA). Transient overexpression of DLL1 
was performed using Lipofectamine 2000 (Invitrogen), 
following the protocol suggested by the manufacturer. 
Clinical gastric tissue samples
Formalin fixed, paraffin embedded tissues from 52 
gastric cancer patients were obtained from the Department 
of Pathology at Baylor University Medical Center (Dallas, 
TX, USA), and from the Department of Gastroenterology, 
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Hepatology and Infectious Disease, Otto-von-Guericke 
at University of Magdeburg (Magdeburg, Germany). 
Forty-three fresh gastric tumor samples, their matched 
normal counterparts and 21 biopsies from healthy 
subjects were obtained during endoscopic procedures 
at the Department of Gastroenterology, Hepatology and 
Infectious Disease, Otto-von-Guericke at University 
Magdeburg. Informed consent was obtained prior to 
procedures. GC histopathological characterization and 
staging of the patients were also collected. Institutional 
Review Board approval was granted for this study from 
Baylor University Medical Center and Otto-von-Guericke 
Department at University Magdeburg.
RNA extraction, RT-PCR and quantitative PCR
RNA extraction from GC cell lines and tissues was 
performed with TRIzol (Invitrogen) and 2 µg of RNA 
were retrotranscribed using random hexamers and MMLV 
reverse transcriptase (Invitrogen). RT-PCR was performed 
using the HotstarTaq Master Mix Kit (Qiagen,Valencia, 
CA). Primers sequences are reported in Table 1. PCR 
products were separated on a 2% agarose gel, stained with 
0.5 µg/ml ethidium bromide and the image was acquired 
under UV illumination (Gel Logic Imaging System, 
Rochester, NY). 
Relative quantification of HES1 and HATH1 was 
performed by quantitative PCR (qPCR) using TaqMan 
Gene Expression Master Mix (Applied Biosystems, 
Foster City, CA) and the TaqMan Gene Expression Assay 
for HES1 (Hs 00172878-m1) and HATH1 (Hs 00245453-
s1). GAPDH was used as the reference gene. The relative 
quantification of gene expression was performed with the 
comparative CT method (2-ΔΔCt), using the correspondent 
wild-type cell line or a pool of healthy subjects as a 
calibrator. Each evaluation was performed in triplicate in 
three independent experiments.
Protein extraction and western blotting 
Total protein extraction from cell lines was performed 
using RIPA Buffer (Santa Cruz Biotechnology, Santa 
Cruz, CA) supplemented with protease and phophatase 
inhibitors (Roche, NJ, USA). Forty micrograms of proteins 
were separated on a 10% SDS-PAGE, transferred onto 
PVDF membrane (GE Healthcare, NJ, USA) and probed 
overnight with the following primary antibodies: rabbit 
anti cleaved Notch1 1:1000 (Cell Signaling Technology, 
Boston, MA), rabbit anti Delta 1:100 (H-265, Santa Cruz 
Biotechnology) and mouse anti-β actin 1:1000 (Sigma-
Aldrich). After washing with TBS-T, the membranes 
were incubated with the anti-rabbit or anti-mouse IgG–
horseradish peroxidase (GE Healthcare) secondary 
antibody at the concentration of 1:5000 for 45 minutes 
at room temperature. Proteins were visualized using the 
ECL Plus Chemiluminescence system and the membranes 
were scanned with a STORM 840 Phosphoimager (GE 
Healthcare). The housekeeping protein β-actin was used 
to normalize protein expression levels. 
MSP and bisulfite sequencing of DLL1 promoter
DNA was extracted using the QIAamp DNA Mini 
kit extraction kit according to the manufacturer’s protocol 
Gene Primer Forward (5’-3’) Primer Reverse (5’-3’) Size(bp)
DLL1 TATCCGCTATCCAGGCTGTC GGTGGGCAGGTACAGGAGTA 297
Notch 1 CAGGCAATCCGAGGACTATG CAGGCGTGTTGTTCTCACAG 429
Jagged 1 TCGCTGTATCTGTCCACCTG AGTCACTGGCACGGTTGTAG 227
Beta-Actin TCACACTGGCATCGTGATGGACTC TCCTGCTTGCTGATCCACATCTGC 642
DLL1 Bisulf ite GGTTTTTAAAGAAAGAAGTTTTGGG CCCAAAACTCCAAACCTACAC 501
DLL1 MSP M Reg1 ATATTCGTCGTCGTCGATC CCGAACCGATTAAAAAACC 100
DLL1 MSP U Reg1 GTATATTTGTTGTTGTTGATT TCCCAAACCAATTAAAAAACC 100
DLL1 MSP M Reg2 AAGGGCGTTTTTTTGTTTAC ATACTACTTCGCTCCACGC 114
DLL1 MSP U Reg2 GGTAAGGGTGTTTTTTTGTTTAT ATACTACTTCACTCCACACACA 114
DLL1 Mouse CTGTGACAAACCAGGGGAGT GACAACCTGGGTATCGGATG 110
GAPD Mouse TCGGTGTGAACGGATTTGGC GGTCGTTGATGGCAACAATC 90
DLL1  Bisulf ite Reg1 Mouse TGGTATTGGTTGAATTTTTGAG CCCAAATATTCAACTTAATTCCC 273
DLL1  Bisulf ite Reg2 Mouse TTTTGGGTTTTTGAAGAAGAAA CCCAACAACCCCTTCTTATTA 408
DLL1 MSP Reg1  M  Mouse GTAGCGGTTGTCGAGTGAC ACCGATAAAACGATAATCCG 112
DLL1 MSP Reg1  U  Mouse GGTAGTGGTTGTTGAGTGAT CACCAATAAAACAATAATCCA 112
DLL1 MSP Reg2  M  Mouse TAAGTGATTTCGGTAGCGAC ACTAAAACGCAAAAACCGA 96
DLL1 MSP Reg2  U  Mouse TTTTAAGTGATTTTGGTAGTGAT TACTAAAACACAAAAACCAAAC 96
Table 1: Primers
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(Qiagen). The methylation status of the DLL1 promoter 
in GC cell lines and tissues was determined by bisulfite 
sequencing and methylation specific-PCR (MSP) after 
treating 1 μg of DNA with sodium bisulfite with the Epitect 
Bisulfite Kit (Qiagen), following the manufacturer’s 
protocol. Modified DNA was used as a template for 
PCR reactions. For the Bisulfite Sequencing, primers 
amplifying a sequence located between -158 and +343 
from the transcriptional start codon and containing 56 
CpGs were selected. PCR amplification was performed for 
14 cycles with annealing temperature of 56.6 °C touching 
down of 0.5°C per cycle for 30 seconds and an additional 
19 cycles with an annealing temperature of 49.6°C for 
30 seconds. Each cycle started with a denaturation at 
95°C and ended with an extension at 72°C, each for 30 
seconds. Two microliters of PCR products were ligated 
into the TOPO vector (Invitrogen, Carlsbad, CA) and, 
after transformation, at least 8 clones per sample were 
sequenced in both directions with M13 primers. MSP 
was performed in two different regions of the promoter, 
spanning respectively between -532 and -432 (Reg1) and 
– 112 and the ATG start codon (Reg2). Primers sequences 
are listed in Table 1.
Methylation and expression analysis of DLL1 in 
INS-GAS mice
Twelve INS-GAS mice were previously infected with 
H. pylori and treated at prescribed intervals with antibiotic 
eradication therapy administered at 8 (n=3), 12 (n=3) or 22 
(n=3) weeks post H. pylori infection (WPI) or not treated 
(n=3) [19]. DNA was extracted from gastric tissues of the 
12 H. pylori infected mice and 3 control mice (not infected 
and not treated) and modified with bisulfite treatment as 
above. DLL1 promoter hypermethylation was analyzed 
by Bisulfite Sequencing in two representative areas of the 
promoter (Reg1: from -617 to -344) and first exon (Reg2: 
from -65 to +220). MSP was performed in two different 
regions of the promoter, spanning respectively between 
-538 to -426 (Reg1) and +119 to +215 (Reg2). RNA 
was extracted from gastric tissues and retrotranscribed 
as above. DLL1 expression was evaluated by RT-PCR. 
Primers sequences are listed in Table 1.
Statistical analysis
Unpaired T-test was used to evaluate the mean 
differences among two groups for the continuous 
variables. Median Test was used to evaluate the median 
differences among two groups for the continuous 
variables. Analysis of variance (ANOVA) was used to 
evaluate the mean differences among three groups for the 
continuous variables. LSD all Pairwise Comparison Test 
was applied to compare groups of continuous variables. 
Fisher Exact test was applied to analyze categorical 
variables. Correlation analysis was used to evaluate the 
relationship between continuous variables.
JMP version 8.02 (Cary, NC; USA) and SAS version 
9.2 (Cary, NC; USA) were used for the statistical analysis. 
Significance was assigned at p< 0.05.
RESULTS
DLL1 expression is epigenetically regulated in 
GC cell lines
In order to evaluate a possible role of the Notch 
system in gastric carcinogenesis, we screened a panel 
of 8 GC cell lines for the expression of Notch1 and its 
ligands DLL1 and Jagged1 at the RNA level by RT-PCR. 
We found that Notch1 and Jagged1 were expressed in the 
entire panel, while DLL1 varied quantitatively with the 
cell lines and was absent in KATOIII, SNU601, SNU719 
and AGS (Figure 1A). Since the DLL1 promoter region is 
characterized by the abundant presence of CpG clusters, 
we hypothesized that an epigenetic mechanism could 
regulate DLL1 expression in GC cell lines. To assess 
whether the DLL1 promoter hypermethylation was 
critical for the suppression of DLL1 expression, the DLL1 
promoter, 5’UTR and 1st exon, spanning from −158 to 
+343 were analyzed by sodium Bisulfite Sequencing. Our 
data showed a strict correlation between DLL1 expression 
and methylation status. A dense methylation was found in 
non-expressing cell lines (KATOIII, SNU601, SNU719) 
while scattered methylated-CpGs were found in expressing 
cells (TMK1, SNU16, MKN1) (Figure 1B). These results 
allowed us to design a MSP on two representative regions 
(Reg1 and Reg2) (Figure 1C).
DLL1 activates Notch1 signaling in GC cell lines 
Since we found a strict correlation between absence 
of DLL1 expression and promoter hypermethylation, we 
evaluated whether DLL1 level could be increased in non 
expressing cell lines by treatment with the demethylating 
agent 5-aza-2’deoxycitidine (5-aza-2’dC). To explore this 
hypothesis, Bisulfite Sequencing of DLL1 promoter pre 
and post 5-aza-2’dC treatment was performed on the AGS 
cell line together with analysis of the DLL1 transcript by 
RT-PCR (Figure 2A). We found that treatment with 5-aza-
2’dC on AGS caused DLL1 promoter demethylation and, 
concordantly, an increased expression of DLL1 RNA. 
In order to confirm these results, the treatment with 
5-aza-2’dC was performed also on SNU719 which also 
showed increased expression of DLL1 RNA and protein 
(Figure 2B). Moreover, we tested the effect of DLL1 
on Notch1 signaling pathway activation. Interestingly, 
DLL1 expression caused an increase in cleaved Notch1 
intracellular domain (NICD) protein together with a 
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significant increase in HES1 (p=0.0018) and a decrease 
in HATH1 (p<0.001) mRNAs (Figure 2B). In order to 
confirm that DLL1 would trigger Notch1 activation, 
we transiently transfected SNU601 with the full DLL1 
coding sequence. As shown in Figure 3, DLL1 ectopic 
expression resulted in increased expression of NICD with 
a consequent significant increase of HES1 (p=0.03) and 
decrease of HATH1 mRNAs (p < 0.007).
DLL1 methylation in clinical samples
We examined the methylation status of the DLL1 
promoter by MSP in GC patients (n=52) and healthy 
Figure 1: DLL1 expression and promoter methylation in GC cell lines. (A) RT-PCR for DLL1, Notch1 and Jagged1. β-actin 
(ACTB) is used as housekeeping gene (B) Bisulfite sequencing: each dot represents a single CpG (black dot for methylated CpG, white dot 
for unmethylated). (C) Representative MSP (Reg 2, U=unmethylated; M=methylated).
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controls (n=21). In the GC group, DNA was selectively 
extracted from the cancerous area of formalin fixed 
paraffin embedded tissues. Our data showed that 20 out 
of 52 primary tumors (39%) exhibited aberrant DLL1 
promoter hypermethylation in at least one region but 
not in any of the samples from healthy controls. We then 
correlated the molecular analysis with the pathological 
characterization, according to Lauren’s classification, 
and we found a significant association between the 
diffuse histotype and the methylation status in the Reg2 
of DLL1 promoter (Figure 4A); it was hypermethylated 
in 11/24 (46%) of the diffuse type of GC samples versus 
1/24 (4%) of the intestinal type (p<0.0009). Interestingly, 
hypermethylation in both regions (Reg1 and Reg2) was 
Figure 2: Treatment with 5-aza-2’deoxycitidine on GC cells. (A) RT-PCR for DLL1 and bisulfite sequencing on AGS pre and 
post 5AZA treatment. (B) MSP for DLL1, RT-PCR for DLL1, Western Blotting for DLL1 and NICD and relative expression of HES1 
and HATH1 evaluated with qPCR on SNU719 pre and post 5-aza-2’deoxycitidine treatment. (* p=0.0018; ** p<0.0001). 5AZA: 5-aza-
2’deoxycitidine; Βeta-actin (ACTB) is used as housekeeping gene.
Figure 3: Over-expression of DLL1 in SNU601. RT-PCR for DLL1, Western blotting for DLL1 and NICD and relative expression 
of HES1 and HATH1 evaluated with qPCR (# p< 0.03; ## p<0.007). Βeta-actin (ACTB) is used as housekeeping gene.
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a unique feature of the diffuse type. No methylation was 
found in any mixed type GC for Reg2 (Figure 4A).
DLL1 expression in clinical samples
In order to assess whether the methylation status of 
the DLL1 promoter could affect the expression of DLL1 
and downstream targets, we performed quantitative PCR 
(qPCR) on RNA extracted from fresh GC patients (n=43) 
and healthy subjects (n=21) for DLL1, HES1 and HATH1. 
Our data demonstrated a significant positive 
correlation between DLL1 and HES1 expression levels 
(r=0.6) (Figure 4B), being significantly stronger in the 
intestinal (p<0.008) or mixed type (p<0.007). A trend 
towards a negative correlation was found between HES1 
and HATH1 in the diffuse and mixed types. However, 
when we correlated the expression of the individual 
genes with the pathological characterization of the tumor 
type, HATH1 expression was specifically associated with 
diffuse and mixed histology (p<0.005) (Figure 4C).
DLL1 expression is not epigenetically regulated 
in INS-GAS mice
We investigated DLL1 promoter hypermethylation 
and mRNA expression on 12 gastric tissues obtained 
from H. pylori-infected and 3 gastric tissues from 
uninfected transgenic control INS-GAS mice treated at 
prescribed intervals with antibiotic eradication therapy 
[19]. The H. pylori-infected mice displayed several 
mucosal abnormalities with progression of the gastritis 
to intestinal-type gastric cancer. DLL1 promoter 
hypermethylation was evaluated by Bisulfite Sequencing 
(Figure 5A) and MSP (Figure 5B). We found no DLL1 
promoter hypermethylation and, concordantly, DLL1 was 
expressed in each tissue sample analyzed (Figure 5C). 
We found a significant increase in DLL1 expression in H. 
pylori-infected mice compared to uninfected (p=0.0253) 
control mice, and a decrease in DLL1 expression in gastric 
tissues from mice treated with the antibiotic eradication 
therapy at 8 and 22 weeks post infection (p<0.05).
DISCUSSION
Notch signaling is a key pathway in the self renewal 
of stem cells, cell fate determination and differentiation 
during embryonic and postnatal development and adult 
cell homeostasis [4, 13, 20]. However, it is known that 
Notch can function as an oncogene in several tumors 
[7], such as T-cell acute lymphoblastic leukemia, breast, 
ovarian and non-small cell lung cancer, with only one 
exception, in the keratinocytes of the epidermis, where 
Notch acts as a tumor suppressor [7, 21-22]. 
In the stomach, Notch signaling activation is involved 
in the developmental phases, controlling the commitment 
of the glandular differentiation and repressing the gastric 
mucin expression. In contrast, its inhibition is required for 
entero-endocrine cell fate determination [6, 12, 14, 16]. 
Recently, Notch signaling activation in lineage-committed 
stomach epithelial cells has been shown to trigger de-
differentiation into stem cells, eventually enhancing 
proliferation and inducing adenomas with focal Wnt 
activation [13]. Moreover, Notch1 activation has been 
associated with gastric cancer progression, at least in part 
through cyclooxygenase-2 [23]. However, the specific 
role of the Notch1 ligand DLL1 in gastric carcinogenesis 
is still unclear. 
We studied the Notch1 cascade in a broad panel of 
Figure 4: Methylation and expression analyses in 
GC patients. (A) Distribution of GC samples according 
methylation status and Lauren’s classification. (B) Correlation 
between DLL1 and HES1 mRNAs in GC patients. (C) 
Association between HATH1 expression and diffuse and mixed 
histology (*p<0.0009;**p<0.005)
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GC cell lines evaluating the expression of Notch1 and its 
ligands DLL1 and Jagged1 at the RNA level. We found 
no differences in the expression of Notch1 and Jagged1 
among the entire panel while DLL1 was selectively 
expressed in SNU16, MKN1, TMK1 and MKN45. In 
contrast, KATOIII, SNU601, AGS and SNU719 showed 
a ‘reciprocal phenotype’ where DLL1 was absent due to 
promoter hypermethylation. The epigenetic regulation 
of DLL1 in these cell lines was further confirmed by 
treatment with 5-aza-2’dC in AGS and SNU719 that 
resulted in up-regulation of DLL1. Importantly, the 
increase in DLL1 expression after 5-aza-2’dC treatment 
resulted in activation of the Notch1 cascade with changes 
in the downstream targets HES1 and HATH1. In agreement 
with these data, the overexpression of DLL1 in SNU601 
confirmed that DLL1 controls Notch1 activation.
According to Lauren’s histological classification, 
GC are divided into intestinal and diffuse types, associated 
with differences in etiology, epidemiology, genetic 
alterations, clinical behavior and response to therapy [24-
MSP
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Figure 5: INS-GAS mice. (A) Bisulfite sequencing performed in two regions of DLL1 promoter on DNA of gastric tissues from four 
mice. Each dot represents a single CpG (black dot for methylated CpG, white dot for unmethylated). (B) MSP for DLL1 on DNA of all 
the 15 mice. (C) Mean relative expression of DLL1 mRNA in each group of mice evaluated with RT-PCR. GAPD is used as housekeeping 
gene. WPI= Weeks Post Infection. *p=0.025; **p<0.05.
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26]. Gastric cancer of the intestinal type progresses as a 
multistep process that is initiated by inflammation, mainly 
due to H. pylori infection, followed by atrophy, intestinal 
metaplasia, dysplasia and cancer [27-28]. In contrast, the 
diffuse cancer type lacks precancerous phases and genetic 
changes underlying its initiation and progression still 
remain unclear, although promoter hypermethylation of 
several genes has been described as a frequent feature in 
the diffuse histotype [25, 29-30].
In the present study, the analysis of the Notch1 
cascade was extended to clinical samples, evaluating the 
expression of DLL1, HES1 and HATH1 mRNA. We found 
that the positive correlation between DLL1 and HES1 
expression levels was significantly stronger in the intestinal 
or mixed type, and as well, a trend toward a negative 
correlation between HES1 and HATH1 was found in the 
diffuse and mixed types. Interestingly, when matching 
HATH1 expression with the histological characterization, 
we found an association between a higher level of 
HATH1 and the mixed or diffuse histotype. Although 
HATH1 is not expressed in the normal stomach [11], a 
higher expression of HATH1 in gastric cancer compared 
to normal mucosa has been reported [31]. This finding 
confirmed previous reports indicating higher level of 
HATH1 expression in mucinous and signet ring colorectal 
cancer samples [32]. Furthermore, our data suggest that 
the differences in DLL1 expression are at least partially 
controlled by epigenetic changes in the DLL1 promoter. 
DLL1 hypermethylation was found as a specific feature 
of diffuse type gastric cancer and characterized almost 
50% of this histotype. Interestingly, although HATH1 is 
associated with the diffuse type of carcinogenesis, our 
data showed hypermethylation of DLL1 promoter only 
in half of the cases. Our data do not exclude that other 
molecular pathways can contribute to HATH1 regulation 
and histological differentiation in the remaining cases. In 
fact, in the stomach, there is a complex network of cross-
regulatory interactions among Notch and several other 
pathways, including Wnt, BMP and Sonic Hedgehog 
[33-34]. It has been demonstrated that HATH1 can be 
degraded by Wnt signaling [35-36] and HES1 expression 
can be controlled by Sonic Hedgehog [37]. On these 
basis, we can also hypothesize that the interaction among 
these pathways can contribute to HATH1 regulation and 
to diffuse type differentiation independently from DLL1 
expression. 
A further confirmation that the DLL1-Notch1 axis 
influences histological differentiation in GC arises from 
an extensive analysis of DLL1 promoter methylation and 
mRNA expression in H. pylori infected INS-GAS mice 
treated at prescribed intervals with antibiotic eradication 
therapy. Indeed, it’s known that H. pylori infected INS-
GAS mice are a model of the intestinal type of gastric 
carcinogenesis [38]. In this model we determined that 
the DLL1 promoter is unmethylated and that DLL1 is 
expressed in all the mice analyzed. Interestingly, H. 
pylori infection causes an up-regulation of DLL1 and 
concordantly the antibiotic eradication therapy causes a 
decrease in DLL1 mRNA levels. This is consistent with 
published findings that DLL1 controls Notch 1 activity 
in mouse intestinal tissue [15] and Notch 1 activation in 
patients with intestinal-type of gastric cancer [39]. 
Among the GC histotypes, the diffuse form 
is associated with higher frequency of peritoneal 
dissemination, metastasis and mortality [25, 40]. In the 
present study we demonstrated that a subset of diffuse 
type GC lacks a functional Notch system, consistent with 
recent results reported by others [39]. These observations 
indicate that in certain kind of cancers Notch inhibitory 
agents, such as gamma-secretase inhibitors, might be 
useless. This data argues that by performing accurate 
molecular characterizations, groups of patients and/or 
subtype of cancers who can benefit from Notch inhibition 
can be accurately identified [41-43].
In conclusion, we demonstrated that DLL1 is 
epigenetically regulated in GC cell lines and DLL1 
expression activates Notch1 signaling. In contrast, in the 
diffuse type of GC, DLL1 epigenetic silencing represses 
the activation of Notch and is associated with high level 
of HATH1, which is a specific feature of diffuse of mixed 
type of gastric cancer. Our results provide evidence that 
Notch1 activation in GC is controlled by the epigenetic 
silencing of the ligand DLL1, and that Notch1 inhibition 
is associated with the diffuse type of gastric cancer.
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